Titre:
  • A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours.
Auteur:Schöffski, Patrick; Awada, Ahmad; Dumez, Herlinde; Gil, Thierry; Bartholomeus, Sylvie; Wolter, P; Taton, Martine; Fritsch, Holger; Glomb, Patricia; Munzert, Gerd
Informations sur la publication:European journal of cancer, 48, 2, page (179-186)
Statut de publication:Publié, 2012-01
Sujet CREF:Cancérologie
Mots-clés:Dose escalation
Phase I
Polo-like kinase (Plk) inhibitor
Solid tumours
Volasertib (BI 6727)
MeSH keywords:Adult
Aged
Antineoplastic Agents -- pharmacokinetics -- therapeutic use
Cohort Studies
Dose-Response Relationship, Drug
Female
Half-Life
Humans
Male
Middle Aged
Neoplasms -- drug therapy -- metabolism
Protein Kinase Inhibitors -- pharmacokinetics -- therapeutic use
Pteridines -- pharmacokinetics -- therapeutic use
Young Adult
Note générale:Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0959-8049
info:doi/10.1016/j.ejca.2011.11.001
info:pii/S0959-8049(11)00874-4
info:scp/84655164874
info:pmid/22119200